The Evolving Role of HER2-Targeting Therapies in Breast Cancer

A medical oncologist provides a comprehensive overview of HER2-targeting agents in breast cancer and considerations to factor into treatment decisions.

Dr Shatsky discusses pertuzumab as a treatment for patients with HER2+ breast cancer, highlighting its mechanism of action as a HER2 dimerization inhibitor and updated data from the APHINITY trial.

Rebecca A. Shatsky, MD, discusses the KATHERINE trial investigating adjuvant trastuzumab emtansine (T-DM1) in patients with residual invasive HER2+ breast cancer following neoadjuvant therapy.

An expert on HER2+ breast cancer discusses exciting advancements in the treatment landscape, highlighting the DESTINY-Breast03 trial and trastuzumab deruxtecan.

Dr Shatsky provides clinical insights on treatment sequencing for patients undergoing treatment for HER2-positive breast cancer.

Rebecca A. Shatsky, MD, looks to the future of HER2+ breast cancer treatment, highlighting unmet needs in the therapeutic space.

Paolo Tarantino, MD, discusses risk factors in early breast cancer, NCCN guideline-recommended therapies, and the transformative impact of HER2-targeted treatments over the past decade.

Dr. Tarantino discuss long-term safety and efficacy findings from the APHINITY trial's 8-year follow-up with pertuzumab, and insights from the NeoSphere study's impact on treatment strategies based on efficacy and safety data.

Dr. Tarantino summarize the trial's design comparing adjuvant T-DM1 versus trastuzumab for residual invasive disease post-neoadjuvant therapy. Discussions include efficacy comparisons, recent 5-year OS analysis results, and the significant IDFS benefits observed with T-DM1 over an 8+ year follow-up period.

Dr. Tarantino discuss the integration of recent trial data into post-neoadjuvant treatment strategies, comparing adjuvant T-DM1 with pertuzumab plus trastuzumab.

Dr. Tarantino provides final thoughts, highlighting unmet needs and future directions in early HER2+ breast cancer on Precision Medicine in Oncology.